Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab. In the expansion stage of the study (Opened 2018), additional patients with epithelial ovarian carcinoma (EOC), melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), renal cell cancer (RCC), bladder cancer (BLC), or triple negative breast cancer (TNBC) will be treated.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study Rgenix.
View study details on ClinicalTrials.gov
For Ovarian/Fallopian/Peritoneal Cancer: Females, 18 years and older, with histologically or cytologically-confirmed epithelial ovarian, fallopian tube or primary peritoneal cancer which is recurrent or persistent Stage 3 or Stage 4.
June 01, 2018